Elranatamab Consolidation Therapy Shows Promise in Deepening Response After CAR-T Treatment in Multiple Myeloma
Key Insights
The phase 2 EPIC study demonstrates that elranatamab consolidation therapy administered 100 days after ide-cel CAR-T treatment deepened responses in patients with relapsed/refractory multiple myeloma (search).
Among 6 patients completing consolidation, responses improved from 4 stringent complete responses to 5, with 3 patients converting from MRD-positive to MRD-negative status.
The fixed-duration elranatamab regimen showed manageable safety with 42% experiencing grade 1 cytokine release syndrome and no unexpected toxicities.
A novel consolidation strategy using elranatamab following idecabtagene vicleucel (ide-cel) CAR-T therapy has shown promising early results in deepening responses for patients with relapsed/refractory multiple myeloma (search), according to initial findings from the phase 2 EPIC study presented at the 2025 International Myeloma Society Annual Meeting.
The study addresses a critical limitation of ide-cel, the first FDA-approved CAR-T therapy for multiple myeloma (search), which achieves overall response rates of approximately 70-85% but has limited durability with a median progression-free survival of about 12 months. The EPIC trial evaluates whether elranatamab consolidation can reinvigorate polyclonal T-cell responses against BCMA (search)-positive myeloma cells when CAR-T cell populations have substantially decreased.
Study Design and Patient Population
EPIC is a single-arm, nonrandomized, prospective phase 2 study evaluating elranatamab as consolidation therapy in patients with relapsed/refractory multiple myeloma (search) after 2 or more lines of treatment who received ide-cel as standard of care. The consolidation regimen begins on day +100 and continues through day +160 following ide-cel infusion.
The elranatamab schedule consists of cycles 1 and 2 administered on days 1, 4 (cycle 1 only), 8, 15, and 22, followed by cycles 3 through 6 administered on days 1 and 15. Patients with serum IgG less than 400 mg/dL receive herpes simplex virus/varicella-zoster virus vaccine and PJP prophylaxis, with intravenous immunoglobulin also recommended.
As of data presentation, 12 patients were enrolled with a median age of 71 years (range: 48-82), 50% female, and 25% presenting with high-risk cytogenetics. Patients received a median of 3 prior lines of therapy before ide-cel (range: 2-6).
Enhanced Response Depth
The study's primary findings demonstrate meaningful improvements in response quality. Following ide-cel treatment, disease responses included 4 patients with stringent complete response (sCR), 2 with very good partial response (VGPR), and 6 with partial response (PR). Among the 6 patients who completed elranatamab consolidation, responses deepened to 5 sCR and 1 VGPR.
Particularly noteworthy were the minimal residual disease (MRD) outcomes. Of the 6 patients with available MRD assessments, 5 achieved undetectable MRD at the 10^-6 sensitivity threshold. Importantly, 3 of these patients converted from MRD-positive status after ide-cel to MRD negativity following elranatamab consolidation.
The median interval between ide-cel infusion and initiation of elranatamab was 113 days (range: 91-158), with 5 patients undergoing step-up dosing in the outpatient setting.
Safety Profile
The consolidation approach demonstrated manageable safety with no new unexpected toxicities. Forty-two percent of patients experienced cytokine release syndrome, with all cases being grade 1. Grade 3 adverse events included neutropenia (33%), anemia (8%), and other events without attribution (50%), including febrile neutropenia, lung infection, hypertension, hypophosphatemia, and neutropenia. One patient required hospitalization due to febrile neutropenia.
Notably, there were no reported cases of immune effector cell-associated neurotoxicity syndrome or grade 3 thrombocytopenia. One patient experienced disease progression with an isolated plasmacytoma 329 days after ide-cel and 219 days after beginning elranatamab consolidation, which was managed with radiation therapy alone without requiring systemic treatment.
Mechanistic Rationale
According to study investigators, the approach is based on leveraging complementary mechanisms between CAR-T cells and T-cell engagers. "We know that there are specific mechanisms of resistance with CAR-T cells and T-cell engagers. Some are overlapping, and some are not," explained Matthew Lei, PharmD, BCOP, clinical pharmacy specialist from Massachusetts General Hospital and lead investigator.
The sequential strategy aims to reinvigorate CAR-T activity while gaining additional activity from the T-cell engager. Data supporting this approach show that sequential T-cell engager therapy prior to CAR-T is inferior compared to CAR-T followed by sequential T-cell engagers.
Clinical Implications
These preliminary results suggest that fixed-duration elranatamab consolidation following ide-cel may represent a viable strategy to deepen responses and increase MRD-negativity in patients with relapsed/refractory multiple myeloma (search). The feasibility of initiating consolidation approximately 100 days post-CAR-T infusion, when cytopenias have commonly resolved and CAR-T cell populations have decreased substantially, supports the clinical practicality of this approach.
At the time of reporting, all patients remained alive, though longer follow-up will be needed to determine the impact on progression-free survival and overall survival outcomes. The study continues to enroll patients to further validate these promising initial findings.